MariMed Inc. announced on September 23, 2026, that it has filed a definitive proxy statement with the U.S. Securities and Exchange Commission (SEC) in connection with a Special Meeting of Stockholders. The purpose of the meeting is to seek stockholder approval of a proposed reverse stock split of the Company’s common stock. The filing was made on September 22, 2026.
The proposed reverse stock split is intended to provide MariMed with greater flexibility to satisfy the minimum share price and other requirements associated with a potential listing of its common stock on a U.S. national securities exchange. If approved by stockholders, the reverse split would be effected in the sole discretion of the Board of Directors. The Board would determine the final ratio based on market conditions and other relevant considerations, including the requirements associated with a potential listing on a U.S. national exchange.
Under the proposal, the Board would be authorized to determine whether and when to implement the reverse stock split at a ratio of between one for fifty and one for one-hundred. The Board would retain the discretion not to implement the reverse stock split if it determines that doing so would not be in the best interests of the Company and its stockholders. No fractional shares would be issued in connection with the reverse stock split; instead, stockholders who would otherwise be entitled to a fractional share would receive a cash payment.
The Special Meeting of Stockholders is scheduled to be held virtually on October 28, 2026, at 9:30 am eastern time, or a later date if adjourned. Stockholders of record as of the close of business on September 4, 2026, will be entitled to vote on the reverse stock split proposal at the Special Meeting.
The definitive proxy statement and other relevant materials are available free of charge at the SEC’s website (www.sec.gov) and on MariMed’s Investor Relations website (www.marimedinc.com).
